Moteur de recherche d’entreprises européennes

Financement de l’UE (6 715 625 €) : OFFENSIVE DE L’ALLIANCE HEALTHCARE POUR DES MÉDICAMENTS INGÉNIEUX CONTRE LES NÉOPLASMES EN HÉMATOLOGIE – PLUS Hor 31/05/2020 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

OFFENSIVE DE L’ALLIANCE HEALTHCARE POUR DES MÉDICAMENTS INGÉNIEUX CONTRE LES NÉOPLASMES EN HÉMATOLOGIE – PLUS

Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be easily diagnosed nor treated. Nowadays most treatments are extremely complex, and advances in patient diagnosis and therapies slow due to the low number of patients per centre. Thus, there is a need to harmonise, store, and analyse the current HM information to speed-up and support the decision-making process for patients’ access to new therapies. HARMONY PLUS takes advantage of the capabilities of the HARMONY Big Data platform to match these unmet needs by expanding its scope to incorporate myeloproliferative neoplasms, including chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; and lymphoproliferative disorders, including Hodgkin’s lymphoma, Waldenström macroglobulinemia and all the other rare HMs not covered by HARMONY Project. In parallel, HARMONY PLUS will continue to refine and define the Core Outcome Sets (COS), especially for these new HMs to ensure the use by researchers of useful common outcomes relevant to all stakeholders. As previously accomplished in HARMONY, HARMONY PLUS is committed to pursue the maximum ethical and legal requirements, particularly to ensure patient’s right to privacy. Data-driven research within Europe will be enhanced by converting the current HARMONY platform into an Integrated Services Platform to serve as a valuable tool to support clinical trial design and use of available data as a control arm. This platform, combined with a HaemoDatabank repository with information about HMs patient biological samples across Europe, will facilitate a more efficient research and clinical trial design, and consequently will promote collaborations with recognised databases outside Europe. From the regulatory point of view, HARMONY PLUS will be a valuable technology tool during the evaluation of new treatments and drugs by also considering the patients’ needs.


Abbvie Inc. 0,00 €
Agencia Espanola de Medicamentos y Productos Sanitarios 75 750 €
Alma Mater Studiorum - Universita Di Bologna 339 000 €
Bayer AG 0,00 €
Bundesinstitut FUR Arzneimittel UND Medizinprodukte 11 250,00 €
Celgene Management Sàrl 0,00 €
Charite - Universitaetsmedizin Berlin 335 250 €
Erasmus Universitair Medisch Centrum Rotterdam 90 000 €
European Hematology Association 664 250 €
European Research Initiative ON CLL e. V. 90 000 €
European Society FOR Blood AND Marrow Transplantation 121 250 €
Fondazione Italiana Sindromi Mielodisplastiche ETS 90 000 €
Fundacio Institut de Recerca Contra La Leucemia Josep Carreras 90 000 €
Fundacion Instituto de Estudios de Ciencias de La Salud de Castilla y Leon 1 606 368 €
Fundacion para La Investigacion del Hospital Universitario La Fe de La Comunidad Valenciana 405 000 €
Genome Research Ltd. LBG 54 000 €
GMV Soluciones Globales Internet SA 502 500 €
Gpoh Gemeinnutzige GmbH 90 000 €
Groupe Francophone des Myelodysplasies 90 000 €
Helsingin Yliopisto 54 000 €
Istituto Nazionale Di Fisica Nucleare 0,00 €
Janssen Pharmaceutica N.V. 0,00 €
Leukanet e. V. 276 125 €
Ludwig-Maximilians-Universitaet Muenchen 90 000 €
Lysarc 0,00 €
Masarykova Univerzita 54 000 €
Medisapiens Oy 32 632 €
Menarini Ricerche S.p.A. 0,00 €
MLL Munchner Leukamielabor GmbH 54 000 €
National Institute for Health and Care Excellence 328 500 €
Novartis Pharma AG 0,00 €
Ospedale Pediatrico Bambino Gesu 90 000 €
Pfizer Ltd. 0,00 €
Stichting Amsterdam UMC 90 000 €
Stiftung ELN Foundation 90 000 €
Synapse Research Management Partners SL 307 750 €
The Chancellor Masters and Scholars of the University of Cambridge 90 000 €
THE Lymphoma Study Association 90 000 €
Universidad de Navarra 90 000 €
Universita Degli Studi Di Torino 90 000 €
Universitaet ULM 90 000 €
University of Newcastle Upon Tyne 90 000 €
VIB VZW 54 000 €

https://cordis.europa.eu/project/id/945406

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.